Abstract
We conducted a comprehensive genome-wide investigation of hearing loss (HL) in 748,668 adult participants of the UK Biobank, the Nurses’ Health Studies (I and II), the Health Professionals Follow-up Study, and the Million Veteran Program. We identified 54 risk loci and characterized HL polygenic architecture, exploring sex differences, polygenic risk across ancestries, tissue-specific transcriptomic regulation, cause-effect relationships with genetically-correlated traits, and gene interactions with HL environmental risk factors. Our transcriptomic regulation analysis highlighted the potential role of the central nervous system in HL pathogenesis. This was supported by the multivariate interaction analysis that showed how genes involved in brain development interact with sex, noise pollution, and tobacco smoking in relation to their HL associations. Additionally, the genetically-informed causal inference analysis showed that HL is linked to many physical and mental health outcomes. These results provide many novel insights into the complex biology and epidemiology of HL in adults.
Competing Interest Statement
Dr Clifford reported receiving personal fees from Decibel Therapeutics outside the submitted work. Dr. S. Curhan serves as a consultant to Decibel Therapeutics. Dr. G. Curhan serves as a consultant to Decibel Therapeutics, AstraZeneca, Shire, Allena Pharmaceuticals, RenalGuard, OrfanBiotech, OM1, and Merck. He receives royalties from UpToDate for being an author and Section Editor. None of the other authors declare any competing interests.
Funding Statement
This research is funded by the National Institute on Deafness and Other Communication Disorders (R21 DC018098, UO1 DC010811). The authors also acknowledge grants from the National Institute on Drug Abuse (R33 DA047527), the National Institute on Mental Health (F32 MH122058), the National Cancer Institute (UM1 CA186107, UO1 CA167552, and UO1 CA176726), the One Mind, and the Marie Sklodowska-Curie Actions (Individual Fellowship 101028810).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of UKB individual-level data has been conducted through the application reference no. 58146. UKB has approval from the North West Multi-center Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval. The use of MVP individual-level data was conducted under project #MVP010 approved by the VA Central IRB. The use of data from the Nurses' Health Studies and Health Professional Follow-Up Study has been approved by the Partners Ethics Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
